On Demand sessions of Ipsen ESMO Virtual Media Briefing - Stronger Together: how combination approaches are revolutionizing the future of Oncology

Ipsen ESMO Virtual Media Briefing - Stronger Together: how combination approaches are revolutionizing the future of Oncology

Ipsen is delighted to offer our ESMO virtual media briefing, titled Stronger together: how combination approaches are revolutionizing the future of Oncology.


The briefing will include video presentations from clinical experts and Ipsen spokespeople who will share further insights on the Phase III CheckMate -9ER data being presented at ESMO in the Presidential Symposium. The briefing will cover the potential impact on current practice, as well as sharing a broader overview of Ipsen’s current pipeline and the expanding utility of Cabometyx® (cabozantinib) in innovative combination approaches.

The virtual media briefing will be made available to all registered participants at 20:00 CEST on Saturday 19 September.

Additionally, for those who register for our virtual media briefing, we are offering the opportunity for 1-2-1 interviews with the speakers and our Ipsen spokespeople.


Click to access the content

20:00 CEST on Saturday 19 September

10 min
Powered by partnerships: Ipsen’s progress in oncology
Ipsen’s 30-year track record in Oncology and the biotech mindset - adapting as the science evolves and the market landscapes changes
Prof. Dr. med. Steven Hildemann

30 min
A new combination designed to target advanced renal cell carcinoma
A deep-dive into the CheckMate -9ER data; why immuno-oncology and tyrosine kinase inhibitor combinations exist and how Cabometyx® can enhance the response to immune checkpoint inhibitors to help patients live longer with improved quality of life
Prof. Dr. med. Jens Bedke

Q&A
Prof. Dr. med. Jens Bedke, Prof. Dr. med. Steven Hildemann

15 min
Navigating a new frontier in renal cell carcinoma – view from the frontline
The challenges of managing kidney cancer, the unmet needs in advanced renal cell carcinoma (aRCC)/metastatic renal cell carcinoma (mRCC) and the new hope the CheckMate -9ER data brings
Dr. Cristina Suárez

Q&A
Dr. Cristina Suárez, Prof. Dr. med. Steven Hildemann

15 min
Stronger together: A pipeline update
Focusing on the new combination approaches under investigation in the pursuit of innovative therapies which deliver for the patient; insight into what's on the horizon for the stacked biologics treatment approach
Dr. Howard Mayer

Q&A
Dr. Howard Mayer, Prof. Dr. med. Steven Hildemann

5 min
Close
Where to find more information about Ipsen’s presence at ESMO and book 1-2-1 interviews with spokespeople
Prof. Dr. med. Steven Hildemann

Speakers

Prof. Dr. med. Jens Bedke
Prof. Dr. med. Jens Bedke
Vice Chairman at the Department of Urology at the University of Tübingen, Germany
Dr. Cristina Suárez
Dr. Cristina Suárez
Vall d'Hebron, Institute of Oncology, Barcelona
Dr. Howard Mayer
Dr. Howard Mayer
Executive Vice President and Head of Research and Development
Prof. Dr. med. Steven Hildemann
Prof. Dr. med. Steven Hildemann
Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety and Patient Affairs